Exelixis
EXEL
#1855
Rank
HK$86.98 B
Marketcap
HK$323.13
Share price
-2.18%
Change (1 day)
25.05%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): HK$18.56

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$18.59. In 2023 the company made an earnings per share (EPS) of HK$5.10 an increase over its 2022 EPS that were of HK$4.45.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$18.56
2023HK$5.1014.61%
2022HK$4.45-22.97%
2021HK$5.78100%
2020HK$2.89-65.09%
2019HK$8.28-53.91%
2018HK$17.97333.96%
2017HK$4.14-260.61%
2016-HK$2.58-58.75%
2015-HK$6.25-42.45%
2014-HK$10.865.3%
2013-HK$10.31

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
HK$81.56 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$13.44-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$101.80 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$28.95 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$59.33 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$23.20 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$28.09 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-HK$28.67-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-HK$6.56-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA